Fracture (FX) Improvement With Teriparatide: FiX-IT Study

Osteoporosis Clinical Trial

— FiX-IT  

Official title:

Fracture (FX) Improvement With Teriparatide: FiX-IT Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01705587
• Other study ID #: PRO12040560 (FiX-IT)
• Status: Completed
• Phase: Phase 4
• First received: October 9, 2012
• Last updated: November 6, 2017
• Start date: December 2012
• Est. completion date: September 2016

Study information

• Verified date: November 2017
• Source: University of Pittsburgh
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This open label comparison study examines the hypothesis that teriparatide given immediately following repair of an atypical subtrochanteric or diaphyseal femoral shaft fracture will enhance healing and improve bone mineral density compared to delayed treatment (after six months) with teriparatide or no treatment with teriparatide (patients who refuse therapy or for whom teriparatide is contraindicated). Patients with up-front teriparatide in addition will have greater quality of life measures and less pain compared to those with delayed or no therapy.

Description:

Up to 24 postmenopausal women with osteoporosis who have been on bisphosphonate therapy for one year or more at any point prior to fracture and have sustained an atypical subtrochanteric or diaphyseal fracture will be enrolled. Subjects randomized to the two intervention arms will self-administer a daily SQ injection of the study medication for 12 months. The primary objective is to demonstrate greater radiologic evidence of healing at 10 weeks in patients on immediate teriparatide compared to those on delayed teriparatide who receive therapy six months after fracture. Secondary end points include (1) radiologic healing at 2, 6, 24, and 46 weeks; (2) increased bone density at 6 and 12 months as assessed by dual x-ray absorptiometry (DXA) at the spine, contralateral hip, and femoral neck; (3) quality of life improvements at 10 weeks and 6 months as assessed by quality of life questionnaire and pain score; and (4) differences in biochemical markers of bone turnover in patient with upfront therapy compared to patients with delayed therapy and patients who refuse therapy or for whom teriparatide is contraindicated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13
• Est. completion date: September 2016
• Est. primary completion date: September 2016
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• postmenopausal women

• with osteoporosis who have been on bisphosphonate therapy for one year or more (all bisphosphonates will be included such as alendronate, risdedronate, ibandronate, or zoledronic acid).

• Patients will also be included if they are on glucocorticoids or other medications known to affect bone mineral metabolism as these are often found in patients with these types of fractures.

• sustain an atypical subtrochanteric or diaphyseal femoral shaft fracture as defined by the the 2010 ASBMR task force. An atypical fracture must include all of the following: (1) a location in the femur distal to lesser trochanter; (2) no trauma or minimal trauma as a fall; (3) transverse or short oblique configuration; (4) noncomminuted; and (5) complete fracture extends through both cortices and may be associated with a medial spike; incomplete fractures involve only the lateral cortex. Patients who have an incomplete fracture can be included if they fall into the 2010 ASBMR task force definition.

Exclusion Criteria:

• men

• children

• those who have had radiation therapy

• Paget's disease

• treatment with teriparatide for two year in the past

• metastatic bone disease

• active cancer

• hypercalcemia

• hyperparathyroidism

• metabolic disease other than osteoporosis

Related Conditions & MeSH terms

• Atypical Femoral Fracture
• Femoral Fractures
• Fractures, Bone
• Osteoporosis

Intervention

Drug:
• teriparatide
20 microgram once-daily subcutaneous injection

Locations

Country	Name	City	State
United States	University of Pittsburgh, Osteoporosis Prevention & Treatment Center	Pittsburgh	Pennsylvania

Sponsors (3)

Lead Sponsor	Collaborator
Susan L. Greenspan	Eli Lilly and Company, University of Pittsburgh

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Radiologic Evidence of Bone Healing	The radiologic indices of fracture healing included (1) cortical continuity on two of four cortices, (2) persistence of alignment, (3) decreased conspicuity of fracture line, and (4) increased callus formation. For each of these indices, healing was graded on a scale of 1 to 4 with 1 = no change (less than 25%), 2 = minimum healing (25-50%), 3 = moderate healing (50-75%), and 4 = complete healing (greater than 75%). A composite score was calculated by summing the subscale scores for the 4 indices. Composite score scale ranged from 4 to 16 with higher scores indicating more complete healing. The primary grading was performed by a radiologist with expertise in musculoskeletal radiology, then independently repeated by a second radiologist, both of whom were blinded to the study allocation.	6, 12 months of treatment
Primary	Radiologic Evidence of Healing	Number of participants with persistence of alignment as determined by a radiologist.	at 10 weeks for immediate teriparatide group
Secondary	Radiologic Healing		at 2, 6, 24, and 48 weeks
Secondary	Increased Bone Density	Percent change in Bone Mineral Density (BMD) as assessed by dual x-ray absorptiometry (DXA) at the spine, contralateral hip, distal 1/3 radius, and femoral neck	at 6 and 12 months
Secondary	Quality of Life Improvements	Assessed by quality of life questionnaire (SF-36). There are 8 subscales each ranging from 0-100 with higher scores indicating better quality of life.	at 12 months
Secondary	Difference in Biochemical Markers of Bone Turnover	upfront therapy group compared to delayed therapy group and no therapy group	intervals over 12-18 months depending on treatment group